The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma
Abstract
Purpose: The discovery of new ovarian cancer biomarkers that are suitable for early disease diagnosis and prognosis may ultimately lead to improved patient management and outcomes. Patients and Methods: We measured, by immunoassay, human kallikrein 6 (hK6) concentration in serum of 97 apparently healthy women, 141 women with benign abdominal diseases, and 146 women with histologically proven primary ovarian carcinoma. We then calculated the diagnostic sensitivity and specificity of this test and examined the association of serum hK6 concentration with various clinicopathologic variables and patient survival. Results: Serum hK6 concentration between normal and benign disease patients was not different (mean, 2.9 and 3.1 μg/L, respectively). However, hK6 in presurgical serum of ovarian cancer patients was highly elevated (mean, 6.8 μg/L; P < .001). Serum hK6 decreased after surgery (to a mean of 3.9 μg/L) in 68% of patients. The diagnostic sensitivity of serum hK6 at 90% and 95% specificity is 52% and 47%, respectively, in the whole patient population. For early stage disease (stage I or II), sensitivity is approximately 21% to 26%. When combined with CA-125, at 90% specificity, sensitivity increases to 72% (for all patients) and to 42% in stage I or II disease. Serum hK6 concentration correlates moderately with CA-125 and is higher in patients with late-stage, higher-grade disease and in patients with serous histotype. Preoperative serum hK6 concentration is a powerful predictor of disease-free and overall survival in both univariate and multivariate analyses. Conclusions: Serum hK6 concentration seems to be a new biomarker for ovarian carcinoma and may have value for disease diagnosis and prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Self-citationGyőrffy, B., Lánczky, A., & Szállási, Z. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0329 · Cited by 970
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
Kulasingam, V., & Diamandis, E. P. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1187 · Cited by 771
Self-citationThe emerging roles of human tissue kallikreins in cancer
Borgoño, C. A., & Diamandis, E. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1474 · Cited by 650
Self-citationNew Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Metadata
- Authors
- Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., Massobrio, M., van der Zee, A. G., Vergote, I., & Katsaros, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-03-15
- Volume
- 21
- Issue
- 6
- Pages
- 1035-1043
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2100048800
- Cited by
- 234
- References
- 1
- FWCI
- 18.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2003.02.022
- The paper
- Diamandis, E. P., Scorilas, A., Fracchioli, S., van Gramberen, M., de Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G. M., Stenman, U.-H., Massobrio, M., van der Zee, A. G., Vergote, I., & Katsaros, D. (2003). Human Kallikrein 6 (hK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.02.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.